Your Sorted CME/CE Activities

Talking PAH: Novel Therapies for Pulmonary Arterial Hypertension
AMA/ANCC/ACPE Activity Archive
Pulmonary arterial hypertension (PAH) is a debilitating and progressive disease characterized by pulmonary artery vasoconstriction and vascular remodeling leading to elevation of pulmonary arterial pressures and pulmonary vascular resistance. Current PAH-specific therapies have significantly improved the outlook for patients by improving functional capacity, pulmonary hemodynamics and reducing hospitalization. PAH remains an incurable disease necessitating further research and treatment options. This webcast provides an update on novel advances in pharmacological therapy in PAH.

This activity will focus on several important aspects of PAH management including a discussion of clinical trial data on emerging therapeutics for the management of PAH; and a review of strategies to optimize outcomes for patients with PAH.
Review the activity and claim AMA, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.

Mardi Gomberg Maitland, MD, MSc Mardi Gomberg Maitland, MD, MSc
Director of Pulmonary Hypertension
George Washington University School of Medicine and Health Sciences
 Marc Humbert, MD, PhD Marc Humbert, MD, PhD
Professor of Medicine, University Paris-Saclay
Department of Respiratory Medicine, Hopital Bicetre
Aaron B. Waxman, MD, PhD Aaron B. Waxman, MD, PhD
Executive Director
Center for Pulmonary Heart Disease

Supported by an independent educational grant from Acceleron Pharma Inc.

Launch Date: December 15, 2021
Release Date: December 10, 2021
Expiration Date: November 30, 2022

November 30, 2022
Mini Module